Anjisheng Biopharmaceutical Technology

Anjisheng Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative therapies for bone, joint, and muscle diseases. The company's pipeline features several first-in-class and best-in-class candidates, including monoclonal antibodies targeting sclerostin and RANKL for osteoporosis and rare bone disorders. Anjisheng operates research and development facilities in Guangzhou and Suzhou, China, and is advancing multiple programs through global clinical trials. By leveraging its expertise in musculoskeletal biology, the company aims to address significant unmet medical needs in aging-related and genetic bone conditions.